Could a targeted drug boost stem cell transplant success in lymphoma?
NCT ID NCT03713580
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This trial tests whether adding the targeted drug venetoclax to standard BEAM chemotherapy before an autologous stem cell transplant can improve outcomes for people with relapsed or refractory Non-Hodgkin lymphoma. Venetoclax works by blocking a protein that helps cancer cells survive, potentially making the chemotherapy more effective. The study enrolls adults whose lymphoma has returned or not responded to prior treatment, and aims to find the safest dose of this combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax added to BEAM chemotherapy before autologous stem cell transplant
- What this could lead to
- If successful, this combination could increase the chance of remission for people with hard-to-treat Non-Hodgkin lymphoma undergoing stem cell transplant.
- What could go wrong
- This is an early-phase trial focused on safety and dosing, so it is not yet known if adding venetoclax improves outcomes. There is a risk of delayed blood cell recovery after transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Could bone marrow from deceased donors cure blood cancers?
- Could an ALS drug clear the fog of chemo brain?
- Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
- Suicide Gene-Equipped t cells aim to make stem cell transplants safer